<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="10.17917/GBQR-BN14" scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
            table { border: 1px solid #dddddd; text-align: left; padding: 8px }
            td, th { border: 1px solid #dddddd; text-align: left; padding: 8px }
            tr:nth-child(even) { background-color: #dddddd }
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><h2>NCL Method ITA-10: Preparation of Human Whole Blood and Peripheral Blood Mononuclear Cell Cultures to Analyze Nanoparticle Potential to Induce Cytokines In Vitro</h2><hr><p>Whole blood or peripheral blood mononuclear cells derived from healthy donor volunteers are cultured in the presence of controls and nanoparticles in order to identify nanoparticle potential to induce cytokine storm. The culture supernatants prepared according to this protocol can be analyzed by commercial assays specific to human cytokines, chemokines and interferons, or by NCL protocols ITA-22 (IL-8), ITA-23 (IL-1b), ITA-24 (TNFa) and ITA-25 (IFNg). NCL uses commercial PBL ELISA kits to test for the presence of type I interferons as well as multiplex kits. There is no harmonized approach as to which type of assay to use or choice between singleplex or multiplex analysis. NCL uses protocol ITA-27 to analyze supernatants by multiplex ELISAs (4-plex, 14-plex and 15-plex).</p><h3>File name: protocols/20240411_12-21-38-441_NCL_Method_ITA-10.pdf</h3><h3>DOI: <a href = http://dx.doi.org/10.17917/GBQR-BN14>http://dx.doi.org/10.17917/GBQR-BN14</a></h3><h3>Resource Type:  Protocol</h3><h3>Data Access: <a href =https://general.datacommons.cancer.gov/#/data>https://general.datacommons.cancer.gov/#/data</a></h3></body></html>